 |
274 Diseases |  |
1060 Trials |
|
1060 Trials |  |
12189 News |  |
| «12...345678910111213...178179» |
- Tevimbra (tislelizumab-jsgr) / BeiGene
Interim results from a prospective multicenter phase II trial of stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC trial). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5464;
The strategy of induction immunochemotherapy showed effective in identifying candidates suitable for dCRT in patients with resectable CESCC. Enrollment is ongoing.
- Tyvyt (sintilimab) / Eli Lilly
The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced lymph node-positive esophageal squamous cell carcinoma: A real world study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5458;
In the real world, sintilimab plus chemotherapy used as neoadjuvant therapy in resectable locally advanced lymph node-positive esophageal squamous cell carcinoma could be effective and manageable toxicity. Clinical trial information: ChiCTR2200058565.
- Molecular and clinical features of pancreatic acinar cell carcinoma: A single institutional experience. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5449;
Better treatment outcome of FOLFIRNIOX/ platinum-based regimens was suggested based on this limited patient dataset. Larger studies are needed to further understand the molecular features of ACC and guide the treatment of this rare entity of pancreatic cancer.
- AiRuiKa (camrelizumab) / HLB Bio Group
A randomized controlled study on perioperative treatment of esophageal squamous cell carcinoma with camrelizumab combined with nab-paclitaxel and cisplatin. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5439;
P2
Further data on optimal adjuvant treatment regimen for pts with or without residual disease will be reported in the future. Clinical trial information: NCT05182944.
- Kaitanni (cadonilimab) / Akesobio
Efficacy, safety and DNA methylation analysis of cadonilimab combined with taxane and cisplatin as the first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC): An open-label, multicenter phase II trial () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5435;
P2
DNA methylation level might be a potential biomarker for guiding patient outcomes. Follow-up is ongoing for survival analysis.
- elraglusib (9-ING-41) / Actuate Therap
Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5429;
P2
The 1801 Part 3 Arm B clinical trial recruitment has been completed. We plan to analyze additional pre-dose plasma samples obtained from approximately 200 patients by April 2024.
- Imfinzi (durvalumab) / AstraZeneca
Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel in resectable biliary tract cancer: A phase II, single-arm, open-label study (DurGAP). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5428;
P2
Neoadjuvant durvalumab combined with gemcitabine/cisplatin/Nab-paclitaxel demonstrated a promising ORR and DCR, with a tolerable safety profile, warranting further investigations in a larger cohort. Clinical trial information: NCT05640791.
- Sulanda (surufatinib) / Hutchmed, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Efficacy and safety of surufatinib, toripalimab, nab-paclitaxel in combination with radiotherapy or surgery in the first-line treatment of esophageal squamous cell cancer: A single-centered prospective clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5409;
The combination ofsurufatinib, toripalimab, nab-paclitaxel with radiotherapy or surgery has demonstrated promising efficacy and a well-tolerated safety profile as a potential first-line treatment for LA or R/M ESCC. This ongoing trial merits further investigation and holds significant implications for clinical practice.
- AiRuiKa (camrelizumab) / HLB Bio Group
Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1st-RT): A single-arm, open-label, phase 2 trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5400;
All patients were treated with camrelizumab combined with albumin paclitaxel and carboplatin for 4 cycles, followed by consolidative radiotherapy. Consolidative radiotherapy following camrelizumab combined with chemotherapy showed potential efficacy and manageable tolerability in patients with advanced oligometastatic ESCC.
- Tevimbra (tislelizumab-jsgr) / BeiGene
PD-1 blockade plus chemotherapy followed by concurrent SBRT with SIB as preoperative therapy for patients with potentially resectable pancreatic cancer: A single-arm phase 2 study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5383;
P2
Anti-PD-1 inhibitor tislelizumab plus AG chemotherapy followed by concurrent SBRT with SIB significantly prolonged mPFS rate, as well as R0 resection rate of surgical patients, and also improved the major pathological response rate. Clinical trial information: NCT05634564.
- Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Envafolimab in combination with lenvatinib and albumin paclitaxel for previously treated advanced gastric/gastroesophageal junction adenocarcinoma: Preliminary analysis of a phase II, two-cohort study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5382;
P2
In patients of advanced gastric cancer who have not previously received PD-1/PD-L1 inhibitors, this second-line combination therapy demonstrates promising preliminary effects. Clinical trial information: NCT06030934.
- elraglusib (9-ING-41) / Actuate Therap
Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5376;
P2
Recruitment for the 1801 Part 3 Arm B phase 2 trial has been completed. Another interim analysis of OS and its correlation to grade 3-4 TIN will be available by April 2024 and will be included in the final presentation.
- albumin-bound paclitaxel / Generic mfg.
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5352;
It seems PD-L1 and TMB were not good predictors to select patients who can more benefit from immunotherapy plus chemotherapy. MDM2 mutation suggest patients tend to less active to immunotherapy-based modality.
- Tyvyt (sintilimab) / Eli Lilly
Neoadjuvant sintilimab, albumin-bound paclitaxel, and carboplatin for locally advanced resectable esophageal squamous cell carcinoma: A prospective phase 2 study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5350;
Preoperative immunotherapy combined with chemotherapy alters the immune microenvironment of locally advanced resectable ESCC. Clinical trial information: ChiCTR2000041081.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5331;
The combination of anlotinib plus penpulimab and nab-paclitaxel as first-line therapy for advanced ESCC demonstrated promising efficacy and manageable safety profile. And the conclusions needed to be confirmed in subsequent trials.
- elraglusib (9-ING-41) / Actuate Therap
Mutational analysis of cfDNA to identify predictive biomarkers in previously untreated patients with metastatic pancreatic cancer receiving the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5328;
P2
Our preliminary analysis of gene mutations in liquid biopsy samples obtained from patients in the ongoing 1801 Part 3B phase 2 trial identified potential predictive biomarkers of clinical outcome in mPDAC patients treated with combination of elraglusib/GnP. Clinical trial information: NCT03678883.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Update results of anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5327;
P2
The conclusion should be validated in more patients consecutively. Clinical trial information: NCT05812430.
- albumin-bound paclitaxel / Generic mfg.
Effectiveness and safety of irreversible electroporation when used for the ablation of stage 3 pancreatic adenocarcinoma: A registry study (DIRECT). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5322;
P
The use of IRE for curative intent tumor ablation alone or in combination with resection following induction chemotherapy in patients with locally advanced Stage 3 PDAC has acceptable safety and is associated with acceptable morbidity and mortality rates in appropriately selected patients. Clinical trial information: NCT03899649.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5307;
P2
Anlotinib plus chemotherapy as first-line treatment has shown promising efficacy and acceptable safety and maybe a favorable option for advanced LMs GI tumors, especially for pancreatic cancer. Clinical trial information: NCT05262335.
- Sulanda (surufatinib) / Hutchmed, AiRuiKa (camrelizumab) / HLB Bio Group
Predictive value of baseline 68 Ga?FAPI PET/CT in the first-line therapy of pancreatic ductal adenocarcinoma (PDAC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5291;
The utility of 68Ga FAPI PET/CT before treatment could reflect the tumor burden and may predict the response of therapy. For those with high uptake of FAPI, therapy targeting FAP might have a promising future.
- Cotellic (cobimetinib) / Exelixis, Roche, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Nab-paclitaxel and gemcitabine (modified) in combination with oral cobimetinib and encorafenib following FOLFIRINOX in patients with metastatic G12D and G12V pancreatic cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5258;
The combination of MEK and BRAF inhibitors with chemotherapy may be potentially active in pancreatic tumors (G12D and G12V). Based on the data presented, Nab-paclitaxel and Gemcitabine in combination with oral Cobimetinib and encorafenib needs to be further explored in a larger cohort of patients.
- Januvia (sitagliptin) / Merck (MSD)
Efficacy and safety of sitagliptin, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5255;
P2
Sitagliptin plus GnP regimen is a feasible regimen with a manageable safety profile. Sitagliptin in combination with GnP regimen shows encouraging antitumor activity in PDAC, meriting continued development.
- Second-line (2L) treatment patterns and clinical outcomes among real-world (RW) patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with FOLFIRINOX (FFX) or gemcitabine + nab-paclitaxel (GnP) in the first-line (1L). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5247;
In a RW sample of mPDAC pts, those with 1L-only had poor survival. Pts with 1L FFX + 2L GnP had a similar survival to 1L GnP + any 2L.
- albumin-bound paclitaxel / Generic mfg.
Phase II trial of biologically optimized schedule of gemcitabine and nab-paclitaxel in metastatic pancreatic cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5229;
P2
9%. Enrolment is ongoing with plans for correlative analysis related to Cav-1.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5168;
P2
Concurrent pyrotinib treatment with TP was associated with a high rate of severe diarrhea. Further biomarker analyses are needed to identify which population would receive great benefit with neoadjuvant pyrotinib therapy in HER2+ breast cancer.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
A prospective, open-label, single-arm phase II clinical study of inetetamab in combination with pyrotinib and albumin-bound paclitaxel for the neoadjuvant treatment of patients with HER2+ early and locally advanced breast cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5113;
7%, and even 72. 7% in HR+ patients.
- Anniko (penpulimab) / Akesobio, Sino Biopharm
The preliminary efficacy and safety results of neoadjuvant phase 2 study of penpulimab combined with taxanes and carboplatin in triple-negative breast cancer (neoTAPPL). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5090;
The study is still ongoing. Clinical trial information: ChiCTR2300071925.
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Avastin (bevacizumab) / Roche
Efficacy and safety of combined anti-angiogenic chemoradiotherapy with PD-1 monoclonal antibody in advanced melanoma: A retrospective study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4954;
This study demonstrates that PD-1 monoclonal antibody in combination with chemotherapy, anti-angiogenic therapy and radiotherapy offers a promising therapeutic option for advanced melanoma. Keywords:Malignant melanoma; Albumin-bound paclitaxel; Bevacizumab; PD-1 monoclonal antibody; Radiotherapy.
- Keytruda (pembrolizumab) / Merck (MSD)
A multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4946;
P2
The results of the phase II study have shown that YH003 in combination with pembrolizumab and nab-paclitaxel, as 1L treatment in patients with unresectable/metastatic mucosal melanoma have promising antitumor activity and response durability and well tolerated. Clinical trial information: NCT05420324.
- albumin-bound paclitaxel / Generic mfg.
Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4905;
Patients who developed an immediate hypersensitivity reaction were more likely to develop a delayed hypersensitivity reaction. Risk factors for development of the rash included Asian race and history of allergy.
- cambritaxestat (IOA-289) / iOnctura
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP) in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4765;
P1/2
Patients in the higher dose cohorts are experiencing robust CA19-9 reductions consistent with ORR. Occurrence of PRs occurred later than compared to historical controls and were durable, suggesting a differentiated mode of action.
- Prediction of therapeutic response and cancer outcomes in solid tumours via in silico clinical trials. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4185;
Blinded evaluation: Using data for paclitaxel, the model correctly predicted that nab-paclitaxel+gemcitabine response rates were higher than gemcitabine in metastatic pancreatic cancer (predicted LOR -0...In all 3 early breast cancer studies, predictions mirrored clinical trial results, adjuvant ECF > CMF, adjuvant TC > AC and adjuvant tamoxifen was superior to capecitabine... Our digital twin model represents transformative technology for clinical trial simulation with strong potential for accelerating and de-risking clinical drug development, and utility for synthetic control arms.
- Tyvyt (sintilimab) / Eli Lilly
Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial. (E451) - Apr 24, 2024 - Abstract #ASCO2024ASCO_4127;
Neoadjuvant sintilimab plus platinum-doublet chemotherapy and sequential TORS achieved satisfactory pathological response, favorable functional preservation and tolerable toxicity in patients with resectable HPV+OPC. Further follow-up is warrant to confirm long-term survival benefits.
- Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01. (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3959;
Upfront multi-omic profiling of PDAC can be successfully incorporated into a multicenter randomized trial. While we have observed PP improved PFS and ITT longer OS favouring GnP in this cohort without gBRCA 1/2 or PALB2m, the benefit of chemo for advanced PDAC patients remains poor, with 43% unable to receive 2 nd line, arguing strongly for the development of 1 st -line biomarker selected strategies.
- albumin-bound paclitaxel / Generic mfg.
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-na (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3958;
P2
EA2186 did not demonstrate a significant difference in efficacy or overall toxicity between two attenuated regimens tested in vulnerable older adults with mPDAC. These results provide important data to guide treatment decisions and goals of care discussions in this vulnerable patient population.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study. (E451) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3947;
A delayed survival advantage, in terms of both the OS and PFS, of concurrent chemoradiotherapy with S-1 was observed, without any additional toxicity burden. An updated analysis with longer-term efficacy/toxicity data is planned to verify the advantage of neoadjuvant chemoradiotherapy.
- azenosertib (ZN-c3) / Zentalis Pharma
Targeting replication stress in pancreatic cancer: A phase II trial investigating azenosertib in combination with gemcitabine in second-line advanced pancreatic cancer. (Hall A; Poster Bd #: 175b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3940;
P2
NCT06015659 is an ongoing phase II clinical trial with safety lead-in that is testing the azenosertib WEE1 inhibitor combined with gemcitabine in patients with advanced pancreatic cancer after progression or intolerance with FOLFIRINOX...JAMA Netw Open. 2023; 6(1):e2249720.
- VCN-01 / Theriva Bio
VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer. (Hall A; Poster Bd #: 175a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3939;
P1, P2
The secondary objectives include time-to-progression (TTP), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), duration of the response (DoR), 1-year OS and PFS rates, and serial changes in tumor markers (Ca19.9). At 31 Jan 2024, the enrollment is ongoing in US and Spanish sites.
- albumin-bound paclitaxel / Generic mfg.
Sequential neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. (Hall A; Poster Bd #: 174b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3938;
P2
Current guidelines suggest modified FOLFIRINOX (mFFX, infusional 5-fluorouracil, oxaliplatin, irinotecan) or GA as the first-line systemic chemotherapeutic regimen in neoadjuvant, adjuvant and palliative setting...These results will have high translational potential for providing mechanistic insight into tumor response, optimizing current management strategies for pancreatic cancer that could be generalizable to other stages of this cancer. The key eligibility criteria include treatment naive histologically diagnosed BRPC or LAPC with measurable disease, ECOG 0,1, optimal organ function.
- Libtayo (cemiplimab-rwlc) / Regeneron, Aphexda (motixafortide) / BioLineRx, Gloria Pharma
CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-na (Hall A; Poster Bd #: 174a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3937;
P2
Exploratory studies include interrogation of the TME using quantitative multiplex immunofluorescence and single-cell RNA sequencing. The randomized phase 2 trial is open to enrollment and one patient has been randomized as of 1/29/2024.
- ivaltinostat IV (CG-745) / CG Invites
A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC). (Hall A; Poster Bd #: 173a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3935;
P1/2
Background: Front-line chemotherapy for patients (pts) with advanced or mPDAC typically consists of mFOLFIRINOX or gemcitabine/nab-paclitaxel given until disease progression or intolerable toxicity...Enrollment in the phase 2 study began in January 2024 across multiple sites in the US. Accrual is anticipated to complete 4Q2024.
- albumin-bound paclitaxel / Generic mfg.
Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM). (Hall A; Poster Bd #: 172b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3934;
P2/3
While oxaliplatin, part of the FOLFIRINOX regimen, represents the most commonly used platinum analogue for PDAC, clinical data shows that cisplatin (in combination with gemcitabine) can produce robust response rates (~70%) specifically in patients with germline BRCA/PALB2-mutated metastatic PDAC...Planned correlatives include ctDNA analysis for BRCA reversion mutations in all patients, as well as whole genome and transcriptome sequencing in an optional biopsy cohort. This study was activated in December 2023.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Imfinzi (durvalumab) / AstraZeneca
TOURMALINE: A phase 3b study of durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer. (Hall A; Poster Bd #: 164a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3917;
P3
Background: In the Phase 3 TOPAZ-1 study (NCT03875235), durvalumab plus gemcitabine + cisplatin (GC) significantly improved overall survival (OS) versus placebo + GC in participants with advanced biliary tract cancer (aBTC) with a manageable safety profile...G-based chemotherapy will consist of G monotherapy, GC (for WHO/ECOG PS 2 participants only), G + oxaliplatin, G + carboplatin, GC + S-1, G + S-1, and GC + albumin-bound paclitaxel...Secondary endpoints include OS, objective response rate, progression-free survival, and duration of response. Enrollment is ongoing and planned in France, Germany, United States, Spain, Italy, Japan, South Korea, and Singapore.
- Imfinzi (durvalumab) / AstraZeneca
Safety of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients (pts) with biliary tract cancer with peritoneal metastases. (Hall A; Poster Bd #: 163a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3915;
P1
Despite advances in standard of care systemic treatments such as combination gemcitabine, cisplatin, and durvalumab (gem/cis/durva), penetration to peritoneal metastases may be poor...If dose-limiting toxicities (DLTs) occur, nab-paclitaxel may be reduced to 70 mg/m 2; the DLT window for each pt is 42 days after the first PIPAC...2. Shroff et al, JCO 2023 LBA490.
- albumin-bound paclitaxel / Generic mfg.
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial. (Hall A; Poster Bd #: 155) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3904;
P2
The lack of survival benefit of GEM/NAB as an adjuvant regimen, as well as SBRT pre-operatively (both shown in studies subsequent to this one) may explain the disappointing results. While an R0 resection for localized PDAC is recognized as essential, our results demonstrate that an R0 resection is not sufficient to cure the majority of PDAC pts who receive NAT with GEM/NAB + SBRT.
- Extracellular (EC) Mucin5AC (MUC5AC) detection after neoadjuvant therapy (NAT) and the risk of recurrence in resected pancreatic ductal adenocarcinoma (R-PDA). (Hall A; Poster Bd #: 151) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3900;
Post NAT EC-MM detection and cellular MUC5AC (MM and IM) expression levels are associated with worse PFS and pathological features. Their role in the treatment of na
- peposertib (M3814) / EMD Serono
ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma. (Hall A; Poster Bd #: 148) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3897;
P1/2
Peposertib 300 mg daily x 14 days in combination with SBRT at a dose of 8 Gy x 5 fractions is the recommended phase 2 dose. A randomized phase 2 study is now enrolling to further assess the efficacy of the combination in patients with LAPC.
- Tevimbra (tislelizumab-jsgr) / BeiGene
Tislelizumab combined with gemcitabine and albumin paclitaxel as preoperative therapy for patients with borderline resectable pancreatic cancer: A prospective, single-arm, phase II trial. (Hall A; Poster Bd #: 142) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3891;
A randomized phase 2 study is now enrolling to further assess the efficacy of the combination in patients with LAPC. Anti-PD-1 inhibitor tislelizumab plus AG chemotherapy displayed promising antitumor activity and acceptable safety profile for patients with BRPC.
- Neoadjuvant fractionated versus hypofractionated chemoradiotherapy in resectable and borderline resectable pancreatic cancer. (Hall A; Poster Bd #: 141) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3890;
Following a shift to HypoFxRT, no apparent compromise in pathologic tumor response, durability of local control, or survival was observed. This data supports the continued use of HypoFxRT within the neoadjuvant Pca treatment paradigm as more convenient alternatives to ConvFracRT.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Comparative effectiveness of NALIRIFOX vs. FOLFIRINOX in pancreatic cancer. (Hall A; Poster Bd #: 140) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3889;
The analysis highlights the importance of AE management for improving quality of life and cost in the recipients of FOLFIRINOX. The economic value for use of NALIRIFOX is very high and outside of any conventional boundary of acceptable value threshold for treatment.